Do you want support to establish your value with real world data?
Here are 6 challenges we can help you to overcome
A leading pharmaceutical company with a strong heritage in diabetes medication felt they needed a business intelligence platform for their field-based Market Access team to query HES, QOF and primary care prescribing data in front of KOLs, payers and medicines optimisation professionals.
Health iQ were successful in a tender process and supplied access to Vantage for multiple users including advanced training. The company used Vantage in hundreds of visits to commissioners and clinicians across the country, for targeting hotspots, planning resource allocation, preparation for meetings and face-to-face engagement.
The company reported impressive success in this type of meeting following the adoption of Vantage and has renewed their license year-on-year since, with this to say about their own experience:
"Your customer service has been exemplary, including helpline availability, swift acknowledgement and response, with clear guidance, to our queries." Decision Support Manager
"There is no doubt that Vantage has helped in my accounts. It has given credibility and has created further opportunities for the sales representatives to build relationships and progress contact with their customers." National Sales Manager
"The tool is very quick and intuitive to use. It also has visually attractive, clear and accurate reports." Market Access and Government Affairs Manager
"The breadth of reports we are able to run is impressive and reflects what our customers are asking for." Healthcare Development Manager
"One of my customers said ‘this is exactly what we need, why are you the only company providing such an excellent service?" Key Account Manager
"Vantage is now integral to our business planning." Healthcare Partnerships Manager
A global leader in specialist medicine for cardiovascular care wanted to communicate their value story to UK payers and KOLs.
They needed to create a digital offering that could support their highly skilled team to offer a compelling picture, both of their product and of their wrap-around services.
Much of their current discussion around value depended upon the juxtaposition of data and metrics on secondary care activity and costs against primary care prescribing. To take this a stage further they required a further set of carefully selected graphs illustrating spending, outcomes and prevalence as well as non-promotional text related to their proposition including appropriate text around PI.
Health iQ enabled this by creating a custom ‘Value Story’ dashboard on the Vantage platform. This began with storyboarding ideas and signing off what messages and data sources were required before development and delivery was achieved with a short turnaround. The custom dashboard has been a great success ensuring our client could continue its momentum in engaging with stakeholders with a more tailored message using the very same secure digital platform and the real world data its team was already familiar with.
Our client wanted to introduce a treatment for long-term conditions with a different posology to the current standard of treatment that would have a significant (but as yet unquantified) impact on services at a local level. The client wanted to find a way to engage Trusts and have conversations based on the most up-to-date real world evidence available both on the value proposition and case for change.
The client’s product (Drug 2) required an 8 weekly injection as opposed to the market leader (Drug 1), which requires a 4 weekly injection followed by a 4 weekly monitoring visit.
We engaged frontline NHS clinicians and staff at ophthalmology departments of various sizes and grades, gathered requirements, collected data and confirmed the pathway options. In the first instance we had to work out if the Trust had the capacity to manage this within the 4 week limit or risk the patient suffering a fall in visual acuity (the key clinical outcome).
Anecdotally the answer was no simply due to pressure on clinics (including heavy locum spend) but it needed modelling and data work to prove why this was the case. We built a simulation model that represented a typical ophthalmology department that a user could adjust with their own localised variables (clinic slots, times, days, staffing, setting, costs etc.) This showed that capacity was being stretched so far that patients were often going beyond the 4 weekly injection time limit for Drug 1.
The model enabled the change to Drug 2, which had an 8 weekly injection and no intervening monitoring. This would inevitably lead to a fall in the pressure on clinics but would decrease revenue. Our model then enabled users to see how that played out including the excess, freed-up capacity.
The model was designed with KAM and clinician input and can be used to identify blocks & efficiencies.
The aim of tool is to provide insight to potential gaps in service where either reassignment of staff or investment is needed.
It considers factors like the number of rooms, staff numbers, timings etc. and was a supportive tool for bigger service redesign project, in which support can take many forms.
The launch of the tool coincided with a significant increase in uptake following engagements with KOLs and HCPs across the country.
A new drug provides advantages over basic nasal packing for Epistaxis treatment with potentially lower A&E waiting times, fewer emergency admissions, lower lengths of stay, lower resource costs with different staff types available for administration and freeing up an ENT bed.
The simulation model could show how a hospital Trust is currently dealing with Epistaxis with a second scenario demonstrating the changes in service with the introduction of the new drug focusing on a particular goals such as:
- Freed capacity in A&E and improved A&E performance
- Reduced Emergency ENT Admissions
- Freed beds in ENT ward
- Lower LoS in ENT ward
- Reduced A&E attendances within 48hrs
Epistaxis simulation provides healthcare professionals with a basis to judge whether the introduction of a new drug would be beneficial to their service and also to quantify the benefit in order to make a case for change.
A major global pharmaceutical company needed to explore all of the oncology data available in the UK for research and evaluation with a focus on the opportunities, gaps and also access.
They commissioned Health iQ following a rigorous process and provided their requirements in a formal kick-off meeting.
We set up a project team to gather and utilise our knowledge of the real world data available based on our extensive NHS heritage. We also ran a stringent systematic review. Furthermore we developed a structured interview process and leveraged our contacts and interviewed senior figures in the field, including at Public Health England and the ABPI. After we conducted a series of interviews we collated the information into a bespoke Cancer Data Map ranking the data available with notes on access requirements.
The company thanked us for this original piece of research and it formed a key part of the strategy for their HEOR and Market Access strategy in Oncology for the next two years with some of the subsequent product launches amongst the most successful in recent years with uptake across the UK.
Our client wanted to raise the profile of respiratory syncytial virus (RSV) as a major burden on the healthcare system in the winter months, and also wanted support in making this case at a local hospital level. It was commonly compared to other viral strains like norovirus and thought of as less of a burden but without the evidence base.
Relevant clinicians were convinced that RSV has a bigger impact than norovirus particularly when the quarantine beds between RSV patient beds were taken into account.
We brought together a range of datasets, and conducted detailed analysis to identify trends that supported this case. This included data on hospital waiting times, cancelled operations, bed capacity and inpatient activity.
We developed this into an ‘RSV Risk Factor’, which could in effect rank hospitals based on how much of an impact a surge in RSV patients would have on them over the winter months. This algorithm was the basis of a range of deliverables:
Our work comprehensively raised the profile, stratified the market and supported engagement with NHS customers, all based around real-world evidence.
Our client was launching a drug within Schizophrenia and wanted to get a clear understanding of the outcomes relating to current products in the same area. They wanted evidence to validate the improved outcome performance (based on clinical trial data) of the new product against existing treatments, in order to support the launch market access plan, as such data is not available in routinely collected datasets, we conducted a 'services evaluation', which involved capturing data directly from patient notes in mental health trust sites. This data was used to map out the existing treatment pathways and associated costs and outcome.
These treatment pathways were then built into a simulation model, in which the impact of the new product could be tested and the resulting potential cost and outcome benefits quantified at a local level.
Retrospective tracking through primary and secondary care. HES patient tracking using our unique pattern matching algorithms. Identification of specific cohorts through on-site secondary data capture process.
Full awareness of the NHS Information Governance ('Caldicott 2') agenda. Experienced in navigating Ethics Committee and Pharmacovigilence.
Our client wanted to assess the benefits of one topical treatment type over others in psoriasis. They hypothesised increased adherence which would lead to real world benefits including a reduced secondary care burden.
The challenge was to design and deliver an appropriately powered real world study that would answer the question of how treatment impact on health outcomes for psoriasis.
We quickly identified that this was a study that would benefit from linking data from Primary Care to Secondary Care.
Health iQ developed a robust protocol and managed the work to acquire the data as part of a compelling research submission with ethics approval and a full set of inclusion and exclusion criteria.
The dataset we worked to extract had 30,000 psoriasis patients for us to conduct a full, non-commercial retrospective cohort study that centred on the time to referral to secondary care.
The result was that we proved a statistically significant reduction in referrals and a delay in disease progression in patients prescribed with the treatment type.
A customer with a strong portfolio in respiratory care needed up-to-date intelligence on their customers' prescribing activity.
They required full UK coverage at GP Practice level, simple visualisation, territory mapping, full visibility of their own brands, as well as their competitors and regular monthly updates so they always have the most up-to-date data.
Health iQ's Vantage RxViewer provided their salesforce with a simple and easy to use system that enabled them to:
- compare prescribing of their drug against a range of competitors.
- identify down to practice level their best and worst customers.
- view historic trends so they could spot changes early.
The client praised Vantage RxViewer as an intuitive, elegant system which just worked and meant they could really leverage their salesforce effectively and build on their successes in respiratory care.